CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
6 results
Search Results
Now showing 1 - 6 of 6
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Clinical, immunologic, and genetic characteristics of 148 patients with natural killer cell deficiency(Elsevier BV, 2025-05) ;Manar Abdalgani ;Evelyn R. Hernandez ;Luis A. Pedroza ;Ivan K. ChinnLisa R. Forbes SatterScopus© Citations 1 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immune Dysregulation Mimicking Systemic Lupus Erythematosus in a Patient With Lysinuric Protein Intolerance: Case Report and Review of the Literature(2021) ;Josefina Longeri Contreras ;Mabel A. Ladino ;Katherine Aránguiz ;Gonzalo P. MendezZeynep Coban-Akdemir<jats:p>Lysinuric protein intolerance (LPI) is an inborn error of metabolism caused by defective transport of cationic amino acids in epithelial cells of intestines, kidneys and other tissues as well as non-epithelial cells including macrophages. LPI is caused by biallelic, pathogenic variants in <jats:italic>SLC7A7</jats:italic>. The clinical phenotype of LPI includes failure to thrive and multi-system disease including hematologic, neurologic, pulmonary and renal manifestations. Individual presentations are extremely variable, often leading to misdiagnosis or delayed diagnosis. Here we describe a patient that clinically presented with immune dysregulation in the setting of early-onset systemic lupus erythematosus (SLE), including renal involvement, in whom an LPI diagnosis was suspected post-mortem based on exome sequencing analysis. A review of the literature was performed to provide an overview of the clinical spectrum and immune mechanisms involved in this disease. The precise mechanism by which ineffective amino acid transport triggers systemic inflammatory features is not yet understood. However, LPI should be considered in the differential diagnosis of early-onset SLE, particularly in the absence of response to immunosuppressive therapy.</jats:p>5Scopus© Citations 18 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related autoinflammatory disease(2021) ;Caridad Martinez ;Frédéric Ebstein ;Sarah K. Nicholas ;Marietta De GuzmanLisa R. Forbes8Scopus© Citations 21 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders(2022) ;Lisa R. Forbes ;Olive S. Eckstein ;Nitya Gulati ;Erin C. Peckham-GregoryNmazuo W. Ozuah14Scopus© Citations 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Failing to Make Ends Meet: The Broad Clinical Spectrum of DNA Ligase IV Deficiency. Case Series and Review of the Literature(2019) ;Aidé Tamara Staines Boone ;Ivan K. Chinn ;Carmen Alaez-Versón ;Marco A. Yamazaki-NakashimadaKarol Carrillo-Sánchez2Scopus© Citations 32 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Novel Heterozygous Mutation in NFKB2 Is Associated With Early Onset CVID and a Functional Defect in NK Cells Complicated by Disseminated CMV Infection and Severe Nephrotic Syndrome(2019) ;Alejandra Aird ;Macarena Lagos ;Alexander Vargas-Hernández ;Jennifer E. PoseyZeynep Coban-Akdemir4Scopus© Citations 27